Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ibrexafungerp versus placebo for acute vulvovaginal candidiasis
2018-004492-12Phase 3Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Mar 2019
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vulvovaginal candidiasis (VVC) comparing Ibrexafungerp with Placebo (2 arms). Primary endpoint: Clinical cure at test-of-cure visit. Started Mar 2019; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on 2018-004492-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004492-12.